Fujirebio Europe Receives Distribution Rights to Market Self-screen's PreCursor-M+ Methylation-specific Molecular Assay, a Powerful Solution to Identify Women at High Risk for Cervical Cancer

GENT, Belgium & AMSTERDAM--(BUSINESS WIRE)--Fujirebio Europe and Self-screen B.V. today announce a commercial collaboration around the distribution of the PreCursor-M+ methylation-specific molecular IVD assay from Self-screen B.V. The test is intended for the qualitative detection of elevated methylation levels of cervical cancer biomarkers and may be used as a triage follow-up test of human papillomavirus (HPV) positive women and women with ASCUS/ LSIL cytology results. It complements Fujirebio's HPV-specific molecular test portfolio.

Read More: BusinessWire - Jornalwebdigital